Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 6/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | PRLHR | P49683 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988678 | 0.88 | GRM5 (0.52) | GRM5PRLHRCYP3A4CYP2C9SLC9A1 | |
| SCHEMBL4990813 | 0.87 | PKM (0.42) | GRM5ALDH1A1SLC6A7TACR3 | |
| SCHEMBL4982974 | 0.87 | GRM5 (0.45) | GRM5KCNH2 | |
| SCHEMBL4988052 | 0.87 | HSP90AB1 (0.42) | GRM5ALDH1A1PRLHR | |
| SCHEMBL4985620 | 0.86 | PTGS1 (0.43) | GRM5CYP2C9KCNH2 | |
| SCHEMBL4983028 | 0.84 | HPGD (0.44) | ALDH1A1 | |
| SCHEMBL4989543 | 0.84 | HPGD (0.45) | GRM5ALDH1A1 | |
| SCHEMBL4989566 | 0.84 | GAA (0.45) | SLC6A7PRLHRSLC9A1KCNH2 | |
| SCHEMBL4987144 | 0.84 | CYP2C9 (0.40) | GRM5SLC6A7PRLHRCYP3A4CYP2C9 | |
| SCHEMBL4984810 | 0.82 | KMT2A (0.43) | GRM5TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | GRM5 231/4885ALDH1A1 3640/4885FASN 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.